Extracorporeal circulation keeps blood moving through artificial tubing, pumps and oxygenators when the heart and lungs cannot perform their normal work. The technology has transformed cardiac surgery, intensive care and life-support medicine, but it creates a persistent biological conflict: blood must remain fluid inside the circuit, while the patient must retain enough clotting capacity to prevent dangerous bleeding. A new study describes a monitoring strategy designed to observe both sides of that problem at once. Using clot-fibrinolysis waveform analysis, the researchers developed a method intended to track how anticoagulants alter clot formation, clot strength and the body’s ability to dissolve clots during extracorporeal circulation.
The challenge begins as soon as blood leaves its normal vascular environment. Contact with artificial surfaces, exposure to air, mechanical stress and changes in blood flow can activate platelets and plasma coagulation proteins. If this activation is not controlled, clots may form inside the circuit, obstructing the oxygenator or pump and potentially releasing embolic material into the patient. Anticoagulants are therefore administered to suppress thrombin generation, the central enzymatic process that converts soluble fibrinogen into insoluble fibrin. Yet excessive anticoagulation can produce severe bleeding, particularly after surgery or in critically ill patients whose coagulation systems are already unstable.
Conventional monitoring does not always capture this rapidly changing balance. Tests such as activated clotting time and activated partial thromboplastin time provide useful information about selected parts of coagulation, but they may not fully represent the interaction among thrombin generation, fibrin polymerization, clot stabilization and fibrinolysis. They can also be influenced by factors unrelated to the administered anticoagulant, including low concentrations of fibrinogen, platelet dysfunction, inflammation, hemodilution and the presence of other drugs. A patient may therefore show an apparently acceptable result on a routine test while still having impaired clot formation or an unexpectedly weak capacity to break down clots.
The method presented in the study approaches the problem as a continuous waveform rather than as a single endpoint. In a clot-fibrinolysis waveform assay, changes in a blood sample are recorded over time as coagulation begins, the clot develops and fibrinolysis takes place. The resulting curve contains information about the speed and intensity of clot formation as well as the subsequent reduction in clot-related signal. Mathematical analysis of the waveform can identify characteristic phases, including the onset of coagulation, the point at which clot development accelerates, the maximum clot-related response and the rate of clot breakdown. In principle, this allows anticoagulant effects and fibrinolytic activity to be interpreted within the same measurement.
The investigators used the approach to examine how anticoagulants influence coagulation and fibrinolysis functions under conditions relevant to extracorporeal circulation. Rather than treating anticoagulation as a simple on-or-off state, the analysis separates several biological events that are often compressed into one laboratory value. A drug may delay clot initiation, reduce the rate of fibrin formation, lower the apparent clot amplitude or modify the later phase of clot dissolution. Distinguishing these effects could help reveal whether a patient’s bleeding risk is caused mainly by excessive suppression of coagulation, inadequate fibrin formation, abnormal clot breakdown or a combination of mechanisms.
This distinction is particularly important because extracorporeal support can alter haemostasis in opposing directions. The circuit may promote coagulation through surface contact and shear forces, while the patient may simultaneously experience platelet consumption, dilution of clotting factors and activation of fibrinolysis. Inflammation and critical illness can further destabilize the system. A monitoring method that evaluates only anticoagulant intensity may miss the consequences of these changes. By following the clotting and fibrinolytic portions of the waveform together, the proposed analysis aims to provide a more integrated picture of the patient’s haemostatic condition.
The study also illustrates why the timing and shape of a laboratory signal can be as informative as its final value. Two samples may reach a similar maximum clot response but arrive there at different speeds, indicating different underlying coagulation kinetics. Likewise, two clots may begin to break down at the same time but dissolve at different rates, suggesting differences in fibrinolytic activity or clot structure. Waveform-derived parameters can therefore offer a richer description than a single clotting time. For extracorporeal medicine, where anticoagulant doses may need to be adjusted repeatedly, that additional information could eventually support more precise and individualized management.
The researchers’ findings indicate that the method can detect anticoagulant-related changes in both coagulation and fibrinolysis functions, establishing a technical basis for its use during extracorporeal circulation. The work is best understood as a method-development study rather than proof that waveform analysis should immediately replace established clinical tests. Before routine adoption, the approach will require validation in larger patient populations and across different extracorporeal platforms, anticoagulant regimens and disease conditions. Investigators will also need to determine how waveform parameters relate to outcomes such as circuit clotting, oxygenator performance, transfusion requirements, postoperative bleeding and thromboembolic events.
If those steps are successful, the impact could extend beyond laboratory measurement. Real-time or near-real-time assessment of clot formation and lysis might help clinicians identify when anticoagulation is insufficient to protect a circuit or excessive for the patient’s current condition. It could also make it easier to distinguish a pharmacological effect from a broader haemostatic disorder. In the long term, such information could contribute to adaptive anticoagulation protocols in cardiopulmonary bypass, extracorporeal membrane oxygenation and other forms of extracorporeal support, where the safest dose is rarely static.
The broader message is that anticoagulation during extracorporeal circulation cannot be reduced to a single number. Blood is a dynamic biological system, and its behaviour changes as it encounters artificial surfaces, mechanical forces, drugs and the patient’s evolving illness. By transforming the entire clotting-to-fibrinolysis process into an analyzable waveform, the new method offers a way to watch that system in greater detail. The technique still faces the crucial test of clinical validation, but it represents a move toward monitoring that measures not only whether blood is clotting, but also how rapidly the clot forms, how strong it becomes and how effectively it can be removed.
Subject of Research: Monitoring anticoagulation, coagulation and fibrinolysis during extracorporeal circulation using clot-fibrinolysis waveform analysis.
Article Title: Development of a novel anticoagulant and fibrinolytic management monitoring method during extracorporeal circulation using clot-fibrinolysis waveform analysis: the effects of anticoagulants on coagulation and fibrinolysis functions
Article References: Journal of Artificial Organs, Springer Nature, 2026.
Image Credits: AI Generated
DOI: 10.1007/s10047-026-01565-8
Keywords: Extracorporeal circulation, anticoagulation, fibrinolysis, coagulation, clot-fibrinolysis waveform analysis, haemostasis, cardiopulmonary support, clot formation, thrombin generation
Tags: anticoagulant management during extracorporeal life supportartificial surfaces and blood activationbalancing thrombosis and bleeding risks in extracorporeal circuitsclot-fibrinolysis waveform monitoring in cardiac surgerydynamic assessment of clot formation and dissolutioneffects of blood-air contact and artificial surfaces on coagulationextracorporeal circulation anticoagulant effectsimpact of mechanical stress on coagulationmonitoring clot strength and fibrinolysis in real-timenovel diagnostic techniques for anticoagulation control
